New Tango Therapeutics (TNGX) director Robert Azelby files initial Form 3
Rhea-AI Filing Summary
Tango Therapeutics, Inc. director Robert Azelby has filed a Form 3, which is an initial statement of beneficial ownership as a company insider. The filing lists him as a director but does not report any stock transactions or current holdings in this excerpt.
Positive
- None.
Negative
- None.
Key Figures
Buy transactions: 0 shares
Sell transactions: 0 shares
Net buy/sell direction: neutral
+1 more
4 metrics
Buy transactions
0 shares
Form 3 transaction summary
Sell transactions
0 shares
Form 3 transaction summary
Net buy/sell direction
neutral
Form 3 transactionSummary netBuySellDirection
Holding entries
0
Form 3 transactionSummary holdingEntries
Key Terms
Form 3, beneficial ownership, reporting person
3 terms
Form 3 regulatory
"has filed a Form 3, which is an initial statement of beneficial ownership"
Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.
beneficial ownership regulatory
"Form 3, which is an initial statement of beneficial ownership as a company insider"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
reporting person regulatory
"The filing lists him as a reporting person in the role of director"
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What does the Tango Therapeutics (TNGX) Form 3 for Robert Azelby show?
The Form 3 identifies Robert Azelby as a director of Tango Therapeutics and serves as his initial beneficial ownership report. In this excerpt, no stock transactions or existing share holdings are listed for him.
Does the TNGX Form 3 for Robert Azelby report any stock purchases or sales?
No, the summary data shows zero buy, sell, acquire, dispose, or exercise transactions. All transaction-related counts and share amounts, including net buy or sell activity, are reported as zero in this filing excerpt.
What is the purpose of a Form 3 for Tango Therapeutics insiders?
Form 3 is used to disclose an insider’s initial beneficial ownership when they become a director, officer, or large shareholder. It establishes a baseline from which future transactions will be reported on Forms 4 or 5.
Are there any derivative securities reported for Robert Azelby in this TNGX Form 3?
No, the derivative summary is empty and derivativeTransactionCount is zero. This indicates no options, warrants, or other derivative positions are reported for Robert Azelby in this particular Form 3 excerpt.
Does the Tango Therapeutics Form 3 show any holdings after the reporting date?
The transaction summary shows holdingEntries as zero, and there are no listed positions. This means the excerpt does not provide any post-reporting share balance or derivative holdings for the reporting person.